Roche Says FDA Decision On Enspryng For Thyroid Eye Disease Expected By October 15

ROCHE HOLDING AG SIX:RO:

• FDA GRANTS PRIORITY REVIEW TO ROCHE’S ENSPRYNG, THE FIRST AND ONLY AT-HOME SUBCUTANEOUS TREATMENT OPTION FOR THYROID EYE DISEASE (TED)

• FDA GRANTS PRIORITY REVIEW TO ROCHE'S ENSPRYNG FOR THYROID EYE DISEASE

• FDA DECISION ON ENSPRYNG FOR THYROID EYE DISEASE EXPECTED BY OCTOBER 15, 2026